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1ABSTRACT
Molecular inversion probe (MIP)-based multiplexed target capture 
for pharmacogenomics analysis
Soo Min Han
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Min Goo Lee)
As the target capture platform for the pharmacogenomics analysis, we designed 
a panel of molecular inversion probes to cover 80 genes which can affect exposure 
and response to drugs. By stepwise rebalancing, probes were optimized to capture 
targets with high coverage (96%) and accuracy (99.8%). The panel features the 
efficient probe preparation as initial microarray-based synthesis of duplex MIPs 
(microDuMIPs) is applied. Target capture and next-generation sequencing (NGS) of 
191 individuals with this panel identified a number of unreported low-frequency
genetic variants in targeted genes. In silico prediction showed genetic variants at 
low frequency enriched for ones with deleterious functional impacts. By further in 
vitro investigation, selected rare or low-frequency variants were validated to alter 
functions in influx/efflux transporters (SLC22A1/OCT1, SLCO1B1/OATP1B1, 
ABCB1/MDR1 and a metabolizing enzyme (CYP2C19). This implicates genetic 
variants at low frequency, which might have been overlooked in past
pharmacogenetic studies, may bear relevance to the inter-individual difference in 
response to drugs. As a follow-up, we applied the platform to capture DNA 
sequences of 90 participants in phase 1 clinical trials for Tacrolimus, an 
2immunosuppressive drug known for large inter-individual variance in 
pharmacokinetics (PK). Besides CYP3A5*3, an established index variant for the 
PK variability, POR*28 and rare variants in UGT1A4 were revealed to be the
account for the part of the PK variability. We verified that the POR*28 allele 
decreased exposure to drug, distinctively in CYP3A5 full expressers. Rare variants 
in UGT1A4 may cause variable extent of glucuronidation as phase II metabolism of 
secondary importance, given that this genetic effect is conspicuous in phenotypic 
extremes with impaired CYP3A5 function (*1/*3 and *3/*3). To the best of our 
knowledge, this is the first time to implicate the association of genetic variations in 
UGT1A4 with variable responses to Tacrolimus. Collectively, POR*28 and rare 
variants in UGT1A4 can explain the PK variance approximately 6% more than 
solely by CYP3A5*3. These results suggest that not only common but also rare 
variants are worth being considered for pharmacogenomic analysis and testing. Our
platform also presents a proof of concept that NGS-based pharmacogenomic testing 
at earlier phase of clinical trials can provide the foundation for understanding 
metabolic pathways of drugs by extensive genetic screening including rare variants
scan. Moreover, this shows that MIP-based multiplexed target capture can be one of 
effective tools to investigate individualized metabolic pathways of drugs.
Key words: pharmacogenomic target sequencing, ADME gene, molecular 
inversion probe, rare variants, tacrolimus
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I. INTRODUCTION
Pharmacogenetics is to study genetic variations predisposed to phenotypic 
variations to drugs with the purposes of reducing unexpected adverse drug reactions 
(ADR) and maximizing clinical benefits of pharmacotherapies. Variants in genes 
affecting pharmacokinetic (PK) and pharmacodynamic (PD) factors are of great 
importance in pharmacogenetics. Whereas PK genes, also referred as ADME 
genens, are linked with drug exposure, influencing absorption, distribution, 
metabolism and excretion (ADME) process, PD genes encode specific drug targets 
and therefore, influence response to drugs directly. While previously developed 
genotyping platforms such as Affymetrix DMETTM Plus panel cover the limited 
number of markers mostly single nucleotide polymorphisms (SNPs) of PK/PD 
genes, recent advances in sequencing technologies enable genotyping in genome-
wide manner. NGS-based platforms have the virtue of the unbiased investigation, 
taking rare and low-frequency genetic variants into account for pharmacogenomic 
analysis. 
41. Molecular inversion probe (MIP)
As innovative strategies of NGS, target-enrichment methods have provided the 
basis for various platforms and sequencing projects. Compared to multiplexing PCR 
and hybridization-based capture, MIP-based capture features high specificity with 
low amount of DNA required.1 Besides, MIP allows various modifications on its 
backbone sequence for more efficient protocols as exemplified by molecular 
tagging.2,3 Due to this feature, MIP used to be applied with microarrays and multi-
color detection for genotyping.4-6 On the other hand, its major drawbacks are that 
synthesizing MIPs at column-based is costly and often the allelic bias disrupts
genotyping accuracy. Nevertheless, MIP-based capture has been evolved into 
various versions with many improvements and proved to fit for the large-scale 
sequencing of several disease conditions.2,7-10 As one of the developed versions of 
MIP-based capture, we previously reported the microarray-based synthesis of 
duplex MIPs (microDuMIPs). It is a less costly and laborious method while keeping
comparable performances by mitigating the allelic bias with unique barcoding.3
2. Association studies in Pharmacogenomics 
Variants of genes affecting pharmacokinetic and pharmacodynamic factors 
contribute inter-individual variability in the phenotypes of drug response to varying 
degrees. Many of these variants and their functional roles have been widely reported 
as the fruition of genome-wide studies of drug responses or ADRs.11,12 However, the 
fruitions are largely limited to common variants as yet.13 Defining rare variations 
intrinsically requires the large-scale investigation, which makes a rare variant-
association study harder and more costly. As implicated in sequencing data of over 
10,000 samples for hundreds of drug target genes, rarer variants were predicted to 
be damaging and maintained at lower frequency, possibly due to the purifying 
selection.14 Nevertheless, only a few studies of rare variant-association were 
performed for phenotypes of toxicity or drug response.15 Therefore, contributions of 
rare variants to phenotypes of drug exposure and response have not yet been fully 
5investigated and the whole picture of roles of common and rare variants in 
pharmacogenomics is still veiled. 
3. Pharmacogenomics in clinical practice
Pharmacogenetic studies finally aim to suggest genetic factors to be reflected in 
decision making at pharmacotherapies. However, clinical implementation of 
pharmacogenetic researches has proceeded slowly. In an effort to adopt 
pharmacogenetics in clinical practice, clinically important genes being paired with 
drugs have been published and updated through the Pharmacogenetics Knowledge 
Base (PharmGKB)16 and Clinical Pharmacogenetics Implementation Consortium 
(CPIC).17 Over 140 drugs have been listed with genetic biomarkers at the FDA 
Table of Pharmacogenomic Biomarkers in Drug Labels.18,19 Meanwhile, a number 
of genetic variants with the clinical actionability are implemented in clinics,20 but 
these are confined to the part of common markers. Recently, preemptive 
pharmacogenomic testing was suggested with proved validity,21 but it is still 
controversial for its utility.22,23
4. Tacrolimus, an immunosuppressant of large PK variability
Tacroilmus is an immunosuppressive drug with large inter-individual 
variability but narrow therapeutic window. A higher level of Tacrolimus can trigger 
nephrotoxicity24 and a lower level than the required concentration can cause acute 
rejections after organ transplantations.25 Therefore, maintaining the optimal 
concentration of Tacrolimus is crucial and also related to prognosis. A canonical 
pharmacokinetic pathway includes two cytochrome P450 3A enzymes (CYP3A4 
and CYP3A5) for metabolizing and ABCB1/MDR1 for an efflux transporter.
Importantly, CYP3A5 plays predominant roles in oxidative metabolism such as O-
demethylation and hydroxylation.26 After the existence of conjugated Tacrolimus to 
glucuronide was reported in human bile,27 uridine 5'-diphosphate 
glucuronosyltransferase (UGT) 2B7 and 1A4 had been suggested for major 
6enzymes for glucuronidation.28,29 However, no significant mechanistic researches on 
phase II metabolism of Tacrolimus has been performed ever since initial discoveries.
Tacrolimus is classified in calcineurin inhibitors, of which mechanism of action 
includes inhibiting the phosphatase activity of calcineurin. It is known that forming 
a complex with FKBP12 renders the increase of the binding affinity of Tacrolimus 
to calcineurin.30 Inhibition of calcinuerin activity, in turn, deactivates the immune
response in T lymphocytes.31,32 According to PharmGKB, previous studies have 
suggested several genetic markers in three canonical genes and other genes such as 
POR, NR1I2, IL10, IL18, PPARA and TLR4 for the PK variance. However, only 
CYP3A5*3 could be introduced as the established genetic marker for a dosing 
guideline of Tacrolimus.33 Other markers have been only suggested with weak 
evidences due to inconsistent results on different cohorts. 
5. Dissertation aims
Here, by applying the microDuMIP technique, we primarily aim to generate the 
optimized MIP set with high coverage and accuracy to capture targeted PK/PD 
genes. The optimized MIP set is to be applied for 191 healthy Koreans. Through 
high-throughput sequencing data, we attempt to investigate the distribution of 
unreported rare or low-frequency variants with reference to databases of population 
genetics. With selected variants being appeared in low frequency, we aim to suggest 
potential roles of those variants in influx/efflux transporters and metabolizing 
enzymes by evaluating functional effects in silico and in vitro. Aside from the 
functional validation, we utilize the MIP set to healthy participants for two phase 1
clinical trials of Tacrolimus. We not only attempt to investigate genetic determinants 
of variability in representative PK parameters but also aim to add the explanatory 
information of genetics regarding the PK variability in Tacrolimus-treated 
individuals by exploring unknown genetic associations of novel or rare variants. 
The aim and progress of the study is depicted (Figure 1).
7Figure 1. The study flow diagram and objectives at each phase.
8II. MATERIALS AND METHODS
1. Design, generation and optimization of MIPs 
To synthesize probes on a microarray, probe sequences were designed by 
fetching desirable lengths of annealing sequences from the reference genome 
sequence (hg 19/Build 37). It is known that most efficient capture is performed by 
optimal melting temperatures(Tm) of two annealing parts of probes. Based on the 
preliminary data that suggested an optimal range of Tm, annealing sequences were
determined while keeping each side of adjacent probes to be overlapped. Each 
probe consisted of 166 bases, of which sequence was constructed with annealing 
and flanking sequences, common linker, and randomly distributed 15 bases as 
molecular tagging (Figure 2). Oligonucleotides were synthesized at a microchip-
base and amplified to get a sufficient amount of probes for capturing target genes 
from hundreds of genomes. For an even and efficient MIP amplification, emulsion 
PCR was adopted with by slight modifications of the previous protocol.34 Mixture 
of water-in-oil (w/o) emulsion was uniformly circulated by using ULTRA-
TURRAX® Tube Drive Control (IKA® Works, Inc., Wilmington, NC, USA). The 
100 µl aliquots of emulsion from the PCR mixture was amplified using the 
following PCR condition: 95°C for 3 min, 35 cycles of 20 sec at 95°C, 30 sec at 
58°C and 30 sec at 72°C, and 10 min at 72°C. PCR-amplified samples were gel-
loaded and purified at the correctly sized bands of 166 bp with the gel extraction kit
(QIAGEN, Valencia, CA, USA). Subsequent PCR was performed with 1 µl of 
previously gel-purified product and its PCR condition was as same as above but for
25 cycles. 17 µl aliquots of gel-extracted product was digested for 16 hr at 37℃ by 
1 µl of EarI (New England Biolabs, Ipswich, MA, USA) with 2 µl of CutSmartTM 
buffer (New England Biolabs, Ipswich, MA, USA) to cleave flanking sequences 
used for PCR amplification. By the gel electrophoresis, enzyme-digested products 
were excised at the correct size and those from 4 lanes of a gel were purified by one
column provided by gel extraction kit (QIAGEN, Valencia, CA, USA).
92. Sample collection
Genomic DNAs of total 281 healthy individuals were collected from clinical 
pharmacology trials performed at Seoul National University Hospital. Among those, 
191 individuals were accompanied with genotypes by the DMET plus panel. We 
obtained two sets of 43 and 47 individuals, who were participated in two 
independent phase 1 clinical trials of oral taking of one or two capsules of 1mg
Tacrolimus as a single dose. All participants were provided with written informed 
consents before their samples were collected.
3. Target capture and high throughput sequencing
Total 1 µg of genomic DNA for each individual and amplified MIPs at 1:100 
ratio were mixed with Ampligase buffer (Epicentre, Madison, WI, USA) and dH2O 
to make a total volume of 15 µl. Hybridization started with denaturing for 2 min at 
94°C, being ramped at 0.1°C per second to 60°C and incubated for 48 hr at 60°C. 
Then, 2 U of AmpliTaq® DNA polymerase (LifeTechnologies, Carlsbad, CA, USA), 
Figure 2. The design of a MIP sequence. (1) Common chip flanking sequences to 
amplify probes after the cleavage from a microarray. (2) Enzyme sites for EarI to cleave 
the flanking sequences after amplification. (3) Sequences to anneal to both sides of target 
regions. (4) Molecular tagging for unique barcodes ranged at 15 bases, composed of 
randomly designated 4 bases. (5) Forward and reverse sequences to amplify from 
hybridized probes for libraries. (6) Backbone sequences to support the length of probes.
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4U of Ampligase DNA ligase (Epicentre, Madison, WI, USA), 10X dNTPs (New 
England Biolabs, Ipswich, MA, USA), 0.2 µL of Ampligase buffer (Epicentre, 
Madison, WI, USA) were added and the mixtures were incubated for 24 hr at 60°C. 
Next, 0.5 µL of Exonuclease I (New England Biolabs, Ipswich, MA, USA) and 0.5 
µL of Exonuclease III (New England Biolabs, Ipswich, MA, USA) were used to 
remove linear DNA fragments at 37°C for 2 hr, and the incubation at 94°C for 4 min
was followed for the deactivation. To amplify and attach barcodes and indexes for 
NGS, 1 µL of a hybridized template, 10 µL of KAPA HiFi polymerase (KAPA 
biosystems, Wilmington, MA, USA), 7 µL of dH2O with 1 µL each of AmpF (5’-
CAG ATG TTA TCG AGG TCC GAC-3’) and AmpR (5’- GGA ACG ATG AGC 
CTC CAA C-3’) primers were mixed and amplified by PCR. Prepared libraries 
were validated for quality control with Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA) and sequenced further by the Illumina HiSeq2500 platform 
according to manufacturer’s instructions.
4. Bioinformatics and in-house programs for genotype calling
Raw sequencing data were separated by sample-specific barcodes. The 
annealing portions (up to 30bp each) in pair-end reads were removed and 15 bases 
of molecular tags were preserved in headers of fastq formats (Figure 3). Only gap-
filled sequences were mapped to the reference genome sequence (hg 19/Build 37) 
using Novoalign (V2.07.18). Local realignments near in-dels were performed and 
quality scores were recalibrated by using the Genome Analysis Toolkit (v2.3.6). 
PCR duplicates were discarded by unique molecular tag information through the in-
house program (Figure 3), which resembles Picard (v1.6.7), a commonly used 
program for NGS data analysis. GATK UnifiedGenotyper (v2.3.6) was used for 
genotype calling for each sample separately. Format converting, sorting, and 
indexing were performed by Samtools(v.0.1.19). Annotation and functional effect 
prediction were performed by PolyPhen-2 (v2.2.2), SIFT (v.1.03) and ANNOVAR. 
11
5. Performance test and variant selection for in vitro assays
The F1 score, defined as 2∙[(precision∙recall)/(precision + recall)], was used for 
setting empirical filters for heterozygous genotype callings. After filtering genotype 
calls with low confidence (sequencing depth ≤ 15 and variant allele frequency ≤
0.3), genotyping by the optimized MIP set was compared with benchmark genotype 
calls for NA12878.35 Total 485 of SNP and in-del genotypes by our platform were 
compared with those by the commercial genotype platform, DMET plus panel 
(n=1927).
Genetic variants that met the following criteria were collected for in vitro assay. 
1) Nonsynonymous variants of SLC22A1, ABCB1, SLCO1B1 and CYP2C19. 2)
Rare variants in the general population, which were discovered only in one or two 
individuals in 191 healthy people and never appeared in databases of dbSNP and 
1000genome project (1000GP).36 3) Deleterious consequences of variants expected 
by at least one functional prediction programs (SIFT37 or polyphen-238). 
6. Site-directed mutagenesis, cell culture and transfection
The expression clones of OATP1B1, OCT1 and CYP2C19 were given by Dr
Sang Seop Lee (Inje University). For mutagenesis, PCR was performed on a 
template vector by using two primers that have a mismatched base at the site where 
to be mutated. Pfu-X DNA polymerase (Solgent, South Korea) with the supplied 
Figure 3. In-house program for trimming barcodes and removing duplicates. The 
barcode information from forward and reverse reads were together preserved in headers 
of fastq formats to remove duplicates from aligned sequencing reads. This helps 
adjusting the allelic bias due to PCR duplicates.
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10X reaction buffer and dNTP mix (10 mM) were used. PCR amplification 
consisted of initial denaturation at 95°C, followed by 30 cycles of denaturation at 
94°C, annealing at 68°C, and elongation at 68°C for 5 min. The PCR product was 
digested by DpnI for 2 hr at 37°C and finally transformed into DH5α E. coli cells
(RBC Bioscience, New Taipei City, Taiwan). Mutant plasmids were isolated using 
the Plasmid DNA Mini-Prep kit (Intron, South Korea) from ampicillin-resistant 
colonies. All mutations were confirmed by sequencing the full-length of all mutant 
clones generated. HEK 293T cells or HEK 293 cells were maintained in Dulbecco’s 
Modified Eagle Medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal 
bovine serum at 37℃. Plasmids were transiently transfected by using Lipofectamine 
Plus Reagent or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
7. Calcein AM efflux assay for ABCB1/MDR1
Two days after transfection with pcDNA3.1(+)-hMDR1 expression vectors, 
HEK 293T cells were dispersed by trypsinization and washed twice with ice cold 
DMEM supplemented with 2 mM L-glutamine and 1 mM sodium pyruvate 
(Invitrogen, Carlsbad, CA, USA). To allow Calcein AM accumulation, the total 
volume of 500 µl of 1 x 106 cells was incubated for 60 min at 37℃ with the 
medium containing 1 µM Calcein AM (Abcam, San Francisco, CA, USA) with or 
without 1 µM Elacridar (Santa Cruz Biotechnology, Dallas, TX, USA), a MDR1 
specific inhibitor. Next, cells were analyzed immediately by a FACSVerse flow 
cytometer (BD Bioscience, San Jose, CA, USA). The median fluorescence of 
Calcein (ex/em 588/527nm) was determined and compared.
8. [3H]-Esteron-3-Sulfate (ES) uptake assay for SLCO1B1/ OATP1B1
Cells transfected in 24-well plates were washed twice with 500 µl of pre-
warmed 37℃ DPBS and incubated in 37℃ water bath for 10 min. After removing 
DPBS in each well, 300 µl of pre-warmed DPBS with [3H]-ES was added and 
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incubated for 5 min for the uptake. Each well was washed with ice-cold DPBS for 3
times and cells were solubilized with 200 µl of 0.1N NaOH by shaking for an hour. 
Once solubilized, cells were transferred to a new 23-well plate with 500 µl of 
OptiPhase SuperMix (PerkinElmer, Waltham, MA, USA) and shaken for 4 hr. The 
radioactivity of [3H]-ES in cell lysates was measured with Beta counter.
9. [14C]-tetraethylammonium(TEA) uptake assay for SLC22A1/OCT1
pcDNA3.1-hOCT2 wild-type and mutants were transiently transfected to HEK 
293 cells. Two days after transfection, cells were washed with DMEM and 
maintained for an hour with serum-free DMEM at 37°C. The washing medium was 
replaced with 1 ml of serum-free DMEM containing 100 μM of [14C]-TEA to allow 
the uptake. The uptake was quenched by washing with 2 ml of ice-cold phosphate-
buffered saline for 3 times. The cells were lysed with 100 μl of cell lysis reagent 
(Promega, Madison, WI, USA). Then, the radioactivity was measured.
10. Purification and expression of CYP2C19 
DH5α E. coli competent cells were transformed with pCW vectors of CYP2C19
wild-type and mutated type. A single colony was inoculated to 100 ml LB 
containing 100 μg/ml ampicillin at 37℃. Each of 50 ml overnight culture was 
transferred to 450 ml TB media with 100μg/ml ampicillin and kept shaken for 3 hr
until the optical density reached the range within 0.4-0.6. After cooling the media 
for an hour, isopropyl β-D-thiogalactopyranoside (IPTG, 0.5mM at final volume) 
and δ-aminolevulinic acid (δ-ALA, 0.5 mM at final volume) were added and 
incubated at 22℃ while shaken at 150 rpm for 3 days. After we confirmed
CYP2C19 expression by measuring Co difference spectrometry, the cultures were 
centrifuged at 5000g for 10 min at 4℃. The pellets were resuspended with 15 ml of 
2X TES/g cells until no clumps were detected at 4℃. After adding 0.6 ml lysozyme, 
15 ml of cold DW was added immediately and incubated for 30 min on ice while 
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stirrred. The suspension was centrifuged at 5000-10000g for 10 min at 4℃ and
supernatants were removed. The sonication buffer of 2 ml/g (wet cells) with DTT 
was added and resuspended with gentle mixing. Then, the mixture was further 
sonicated and centrifuged at 10000g for 20 min at 4℃. The supernatants were
centrifuged at 150000g for 2 hr and the isolated membranes were resuspended with 
10 ml of 1X TES buffer assuming 1 ml/g (wet cells).
11. 4’-hydroxylation assay of S-mephenytoin by CYP2C19
We reconstituted CYP2C19 protein (5 pmol) with cytochrome b5 (10 pmol), 
0.05 μmol sodium cholate and human NADPH-P450 oxidoreductase (20 pmol) in 
TES buffer (pH 7.4). The hydroxylation reaction was initiated by incubating with 10
mM NADPH at 37℃. For the reaction, 200 μM of S-mephenytoin was used. The 
enzyme activity for 4’-hydroxy S-mephenytoin was quantified by a Qtrap 4000 
liquid chromatography/tandem mass spectrometry system (Applied Biosystems,
Foster City, CA, USA) equipped with electrospray ionization.
12. Statistical analysis
For results of in vitro investigation, data was presented as mean ± SEM for at 
least three experiments. Statistical significance was marked from Student’s t-tests, 
at which P < 0.05 was regarded as statistically significant. For comparison, unpaired 
T-test was performed for two groups with equal variances from F-test. Welch’s 
corrected T-test was performed for two groups with unequal variances from F-test. 
Linkage disequilibrium(LD) was analyzed using Haploview software39 within 
500kb from an index locus. For rare variants of allele frequency at 0.01, simple 
gene-based burden tests were performed for all samples and 3 metabolizers groups 
categorized by CYP3A5*3 genotypes. Initially, we compared means of carrier and 
non-carrier of rare variants in each gene with unpaired T-test within pooled samples 
(n=90). Among PK parameters, we used the area under the blood concentration time 
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curve at last quantifiable concentration, AUClast, for an index measure of drug 
exposure. Dose-adjusted AUClast was used for the analysis of pooled samples
simply by dividing AUClast values by the dose. For genes with significant P-values, 
we further investigated effects of rare variants in each set (n=43 and 47). Multiple 
linear regression was used to calculate R2 by adding genetic determinants including 
CYP3A5*3 genotypes. The significance of adding new genetic factors was checked
using ANOVA, comparing the model before and after adding new genotypes. We 
defined the difference of R2 as the explanatory information supplemented by each 
genetic factor.
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III. RESULTS
1. Targeted capture platform was generated based on MIP technique for 
80 genes on drug response and exposure
We initially designed 10908 probes to capture exons, promoter regions, and 
splicing junctions of 80 genes, covering all transcript isoforms reported (Table 1A, 
Figure 4A). Specifically, 600kb of upstream, +50bp/-10bp of each splicing 
junctions and 100kb of downstream for each gene were included as target regions.
We also designed probes to target markers of the DMET Plus array including single 
and multi-nucleotide polymorphisms, insertions and deletions (Table 1B, Figure
4B). Two probes per each target loci were designed to prevent missing targets. We 
adopted the microDuMIP method with minor modifications.40 Molecular tags of 15
bases were designated at two each sides of the probe sequence with 9 bases and 6 
bases and preserved to NGS data (Figure 4C). These barcodes were introduced to 
allow the number of distinct molecular tags to be greater than total number of 
probes at the time of the synthesis. Optimization of MIPs was repeated for 
improving overall capture performances (Figure 5A). It is known that the adequate 
Tm is one of valuable predictors of the capture efficiency as it is amendable when
designed.7 Annealing sequences for MIPs were fetched from the reference genome 
sequence while lengths and locations were adjusted (Figure 5B). The length of arm 
sequences ranged from 15 bp to 27 bp. Next, the ideal range of Tm for two 
annealing sequences was empirically defined at the pilot stage with 16 samples 
(Figure 5C). Most efficient Tm ranged from 55 to 62.5℃. Interestingly, the capture 
efficiency was relatively well preserved even for probes with only one annealing 
sequence, of which Tm fit within the best range. This suggested that only one 
annealing portion with the sufficient capture performance was enough to support 
another annealing part to better hybridize to target sequences. After we set less 
efficient probes by the mean sequencing depth over pilot samples, we rebalanced 
those to fit to the ideal range of Tm by adjusting the length of annealing sequences 
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flexibly or shifting the location from GC- or AT-rich regions. We increased the 
amount of probes with low capture performance despite the ideal range of Tm. Two 
independently generated probe sets of the original and rebalanced were mixed at 
ratio 1:1, which showed better capture performances in a breadth of coverage (%) 
over target regions (Figure 6A). We confirmed that there was no remarkable 
competition between the original and rebalanced probes that blocked each other 
from capturing target sequences. Overall capture performance of MIPs was 
improved and the proportion of poorly performing MIPs decreased after 
rebalancing (Figure 6B).
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Table 1. 80 genes and markers targeted by the MIP panel
A. 80 Target genes
Class Gene Full name
Phase I1 ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide
Phase I ADH1B Alcohol dehydrogenase 1B (class I), beta polypeptide
Phase I ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide
Phase I ALDH1A1 Aldehyde dehydrogenase 1 family, member A1
Phase I CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1
Phase I CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2
Phase I CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6
Phase I CYP2B6 Cytochrome P450, family 2, subfamily B, polypeptide 6
Phase I CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19
Phase I CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 8
Phase I CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9
Phase I CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6
Phase I CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1
Phase I CYP2J2 Cytochrome P450, family 2, subfamily J, polypeptide 2
Phase I CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4
Phase I CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5
Phase I CYP4F2 Cytochrome P450, family 4, subfamily F, polypeptide 2
Phase I DPYD Dihydropyrimidine dehydrogenase
Phase I EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic)
Phase II2 GSTM1 Glutathione S-transferase mu 1
Phase II GSTP1 Glutathione S-transferase pi 1
Phase II NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase)
Phase II NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase)
Phase II SULT1A1 Sulfotransferase family, cytosolic, 1A, phenol-preferring, 
member 1
Phase II TPMT Thiopurine S-methyltransferase
Phase II UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1
Phase II UGT1A10 UDP glucuronosyltransferase 1 family, polypeptide A10
Phase II UGT1A3 UDP glucuronosyltransferase 1 family, polypeptide A3
Phase II UGT1A4 UDP glucuronosyltransferase 1 family, polypeptide A4
Phase II UGT1A5 UDP glucuronosyltransferase 1 family, polypeptide A5
Phase II UGT1A6 UDP glucuronosyltransferase 1 family, polypeptide A6
Phase II UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7
Phase II UGT1A8 UDP glucuronosyltransferase 1 family, polypeptide A8
Phase II UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9
Phase II UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15
19
Phase II UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7
Transporter ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1
Transporter ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1
Transporter ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11
Transporter ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2
Transporter ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3
Transporter ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4
Transporter ABCC7 ATP-binding cassette, sub-family C (CFTR/MRP), member 7
Transporter ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1
Transporter ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2
Transporter SLC10A1 Solute carrier family 10 (sodium/bile acid cotransporter 
family), member 1
Transporter SLC15A1 Solute carrier family 15 (oligopeptide transporter), member 1
Transporter SLC15A2 Solute carrier family 15 (H+/peptide transporter), member 2
Transporter SLC22A1 Solute carrier family 22 (organic cation transporter), member 1
Transporter SLC22A11 Solute carrier family 22 (organic anion/urate transporter), 
member 11
Transporter SLC22A12 Solute carrier family 22 (organic anion/urate transporter), 
member 12
Transporter SLC22A2 Solute carrier family 22 (organic cation transporter), member 2
Transporter SLC22A3 Solute carrier family 22 (extraneuronal monoamine 
transporter), member 3
Transporter SLC22A4 Solute carrier family 22 (organic cation/ergothioneine 
transporter), member 4
Transporter SLC22A5 Solute carrier family 22 (organic cation/carnitine transporter), 
member 5
Transporter SLC22A6 Solute carrier family 22 (organic anion transporter), member 6
Transporter SLC22A8 Solute carrier family 22 (organic anion transporter), member 8
Transporter SLCO1A2 Solute carrier organic anion transporter family, member 1A2
Transporter SLCO1B1 Solute carrier organic anion transporter family, member 1B1
Transporter SLCO1B3 Solute carrier organic anion transporter family, member 1B3
Transporter SLCO2B1 Solute carrier organic anion transporter family, member 2B1
PD ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
PD ADRB2 Adrenergic, beta-2-, receptor, surface
PD BRCA1 Breast cancer 1, early onset
PD COMT Catechol-O-methyltransferase
PD DRD2 Dopamine receptor D2
PD F5 Coagulation factor V (proaccelerin, labile factor)
PD G6PD Glucose-6-phosphate dehydrogenase
PD HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
PD MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH)
20
PD NQO1 NAD(P)H dehydrogenase, quinone 1
PD P2RY1 Purinergic receptor P2Y, G-protein coupled, 1
PD P2RY12 Purinergic receptor P2Y, G-protein coupled, 12
PD PTGIS Prostaglandin I2 (prostacyclin) synthase
PD SCN5A Sodium channel, voltage-gated, type V, alpha subunit
PD TYMS Thymidylate synthetase
PD VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor
PD VKORC1 Vitamin K epoxide reductase complex, subunit 1
Modifier AHR Aryl hydrocarbon receptor
Modifier NR1I2 Nuclear receptor subfamily 1, group I, member 2
B. Affymetrix DMETTM Plus panel 
1928 markers of 231 genes
(1842 SNPs, 2 DNPs, 1 TNP, 39 insertions, 42 deletions, 1 in-del, 1 STR)
(A) 80 genes are comprised of genes encoding Phase I and II metabolizing enzymes,1,2 drug 
transporters and other genes related to drug response. (B) It also target known markers by 
Affymetrix’s DMET Plus panel. DNP, Double Nucleotides polymorphism; TNP, Triple 
Nucleotides polymorphism; STR, Short Tandem Repeats. 
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Figure 4. Molecular inversion probes (MIP) design and molecular tagging 
with barcodes. The design scheme of MIPs to capture exons, promoter regions, 
and splicing junctions of all transcript isoforms of 80 genes (A) and markers of 
Affymetrix’s DMET plus array (B). (C) Molecular barcode tagging of randomly
designated 15 bases, preserved to paired-end sequences from NGS. AmpF/R 
sequences were used to amplify gap-filled probes for NGS libraries.
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Figure 5. Optimization of MIPs and parameters for the capture efficiency. 
(A) The flowchart of stepwise rebalancing. The process was repeated until the 
improvement in the capture performance was confirmed. (B) The diagram of 
fetching two annealing arm sequences from the reference sequence. Variable 
lengths and locations were considered to fit in the best Tm range. (C) The 
predictor of the capture efficiency for 10908 MIPs. The mean sequencing depth 
over the target region by each MIP was calculated and regarded as an index of the 
capture efficiency. These were color-coded and scaled by dots in the plot.
23
Figure 6. Performance comparison of MIPs after rebalancing. (A) Overall 
improvement of a breadth of coverage (%) over target regions before and after 
rebalancing MIPs. (B) MIPs with low performance were improved to capture 
targets with higher coverage. The proportion of poorly performing MIPs decreased 
after rebalancing.
24
2. Optimized MIPs enable efficient sequencing of ADME and PD genes 
with high coverage and accuracy
The optimized MIP set was applied to capture target sequences from 191 
healthy Koreans (Figure 7). Exploring the breadth of coverage over target regions, 
median 96% of targets were captured and 92% at 15X sequencing depth. Covered 
regions were sequenced to the median depth of 400X, showing the uniform 
distribution of coverage. The MIP sets comprised of two kinds of probes, which
were exon-targeting MIPs for 80 genes and locus-targeting MIPs for markers of 
DMET plus panel. For locus-targeting MIPs, median 98% of targets were captured 
and 96% at 15X sequencing depth.
Figure 7. The summary statistics of sequencing data for 191 Koreans. The 
breadth of coverage was depicted at the left-Y-axis and mean depth at the right-
Y-axis. Median 96% of targets were covered and 92% at 15X sequencing depth 
with median NGS depth of 400X.
25
We set the empirical filter for the genotype calling, especially for heterozygous 
calls. By adjusting the filter conditions for sequencing depth and allelic depth, the
F1 score was calculated for genotype comparisons between the MIP set and 
validated genotypes of NA12878. We defined the filter as sequencing depth ≥ 15 and 
variant allele frequency ≥ 0.3 (Figure 8). After filtering genotype calls with low 
confidence, genotypes by the MIPs were compared with benchmark genotype calls, 
validated by integrating multiple sequencing data.35 Total 485 of SNP and in-del 
genotypes were 99.8% concordant with the validated genotypes with 98.1% 
sensitivity (Table 2). When compared to using the commercial genotype platform, 
DMET plus panel, genotypes by our platform showed 99.4% concordance with 97% 
sensitivity (Table 2).
Figure 8. F1 Scores as adjusting filtering conditions. As variant allelic depth
(X-axis) and sequencing depth (Y-axis) were adjusted, the empirical filtering 
condition was set by measuring the F1 score, which represents PPV and recall 
(sensitivity).
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Table 2. Comparison of genotyping by the optimized MIP set and existing 
platforms
Affymetrix DMETTM
Plus panel
Validated genotype for 
NA12878
Platform Array WES, WGS
Number of sites common 1927 485
Number of Samples 
compared
191 1 (NA12878)
PPV (%) 99.4 (mean) 99.8
Sensitivity (%) 97 (mean) 98.1
Positive Predictive Value (PPV, %) and Sensitivity (%) of genotypes by the optimized MIP 
set, when comparing to those from DMET plus panel and integrated multiple data. For 
comparison with DMET plus panel, the mean of 191 samples were described in the table.
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3. Targeted sequencing of ADME genes for healthy Koreans reveals many
unidentified functional variants at low allele frequency 
With variant profiles for 191 healthy Koreans, we explored the distribution of 
nonsynonymous and synonymous variants by their allele frequencies. The ratio of 
nonsynonymous to synonymous variants (NS:S ratio) had a tendency to increase as 
variants were detected in lower frequency (Figure 9A). In fact, the number of 
samples (n=191) was not enough to detect very rare variants. Nevertheless, the 
tendency indicated that many of function-altering variants have been under the 
purifying selection, which made those variants kept in low frequency in the given 
population. This was consistent with the previous results of sequencing 202 drug 
target genes over ten thousands of people.14 By in silico functional prediction 
programs (SIFT37 and Polyphen-238), variants at low allele frequency were more 
likely to have damaging impacts on functions of proteins (Figure 9B). The result
suggested that not all but many of genetic variants in low frequency may have 
damaging effects on protein functions. In pharmacogenetics, it suggested that 
genetic variants in ADME or PD genes, even at low frequency, can have substantial 
effects on response and exposure to drugs.
In an attempt to evaluate functional consequences, unprecedented variants,
which were observed only once or twice in 191 samples, were selected (Table 3). 
Due the fact that the number of samples was not sufficient to detect rare variants,
we checked databases of population genetics such as dbSNP and 1000GP. 
Considering that more than thousands of samples were involved in each database, 
target variants for functional evaluation were selected if never reported in public 
databases. Reported variants with different variant alleles were regarded as novel. 
Variants with predicted damaging effects were selected preferably in influx/efflux 
transporters (SLC22A1/OCT1, SLCO1B1/OATP1B1 and ABCB1/MDR1) and 
metabolizing enzyme (CYP2C19). 
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Figure 9. Properties of genetic variants by allele frequency (AF) observed in 191 
Koreans. (A) The portion of nonsynonymous variants was elevated at low allele 
frequency. (B) Variants at lower frequency were predicted to be functionally deleterious 
by two in silico functional prediction programs (Polyphen-2 and SIFT). MAF, Minor 
Allele Frequency.
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Table 3. Unreported variants at low allele frequency for in vitro functional 
validation 
Gene Variant Protein 1 Frequency pph-2 SIFT Novelty 2
SLC22A1 c.C98T p.A33V 2/191
Possibly 
damaging
Damaging Novel
SLC22A1 c.A272G p.Y91C 1/191
Probably 
damaging
Damaging Novel
SLC22A1 c.G1219A p.A407T 1/191
Probably 
damaging
Damaging Novel
SLCO1B1 c.G250T p.V84L 2/191
Probably 
damaging
Damaging Novel
SLCO1B1 c.G1213T p.V405F 1/191 Benign Tolerated
Different
allele 3
ABCB1 c.G751A p.G251R 1/191
Probably 
damaging
Damaging
Different
Allele 4
ABCB1 c.C2278G p.L760V 1/191
Possibly 
damaging
Tolerated Novel
ABCB1 c.G3385A p.E1129K 1/191 Benign Damaging Novel
CYP2C19 c.C629A p.T210N 1/191 Benign Damaging Novel
CYP2C19 c.A818C p.K273T 1/191 Benign Damaging Novel
1 Annotations were based on NM_003057, NM_153187 for SLC22A1, NM_006446 for 
SLCO1B1, NM_000927 for ABCB1 and NM_000769 for CYP2C19.
2 Novelty: not previously reported in dbSNP or 1000 GP.
3 Different allele was reported previously with rs ID, rs376060151 (G/A).
4 Different allele was reported in ABCMdb,41 in several publications regarding p.G251V.
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4. In vitro functional assay showed function-altering effects of genetic 
variants in four ADME genes (SLC22A1, SLCO1B1, ABCB1 and 
CYP2C19)
Next, we evaluated functional consequences of unreported rare and low-
frequency variants. We prioritized target genes for in vitro assays among Phase I 
metabolizing enzymes and influx/efflux transporters. Then, we investigated clinical 
evidences of each gene paired to drugs from Pharmacogenomics Knowledge Base 
(PharmGKB)42 and the FDA Table of Pharmacogenomic Biomarkers in Drug Labels. 
Among those genes, 4 ADME genes were chosen as reference substrates were 
available. Importantly, CYP2C19 was the second most frequently associated gene 
with multiple drugs among FDA-informed pharmacogenomic biomarkers. The rest 
of three genes of influx/efflux transporters were associated with multiple drugs as
clinical evidences to varying degrees (Figure 10). 
Figure 10. Clinical relevance of 4 ADME genes to drugs. Data was extracted 
from public databases (PharmGKB and FDA pharmacogenomic biomarkers). The 
strength of evidence (bottom left) was presented as PharmGKB. Genetic markers 
of Level 1a represent established markers, as included in dosing guidelines.
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Selected rare and low-frequency variants for 4 genes were tested with the 
reference substrates and most of the variants significantly reduced intrinsic 
functions of proteins (Figure 11). Two of three variants in SLC22A1/OCT1 
consistently reduced the uptake of [14C]-TEA in HEK 293 cells that were 
transfected with mutated OCT1 plasmids (Figure 11A). Because OCT1(SLC22A1) 
primarily functions in the hepatic uptake of cationic drugs,43 function-reducing 
variants such as p.A33V and p.Y91V may reduce the hepatic excretion and alter the 
exposure and response to OCT1 substrate drugs. Since these two variants are not 
directly related to forming substrate binding pockets,44 reduced function of OCT1 
can affect the wide variety of OCT1 substrate drugs. Besides, consequences of two 
variants in SLCO1B1/OATP1B1 were as predicted by in silico predictions. Only 
p.V84L variant significantly reduced the influx of [3H]-ES depending on its 
concentration (Figure 11B). As implied from statin-induced myopathy by common 
genetic variants,45 the decreased function of OATP1B1 by p.V84L can be possibly 
associated with ADRs of substrate drugs. Also, two of three variants in 
ABCB1/MDR1 reduced the efflux of Calcein, resulting in the increased intracellular 
fluorescence (Figure 11C). Since MDR1 is one of the largely distributed proteins in 
the body,46 the diminished function may cause the direct influences not only on 
absorption but also elimination of MDR1 substrate drugs. Furthermore, two variants 
of CYP2C19 significantly lowered 4’-hydroxylation function for (S)-Mephenytoin
(Figure 11D). Two variants are likely to affect the catalytic efficiency of CYP2C19 
for other substrate drugs as well because two sites (Thr210 and Lys273) are not 
within the specific binding sites of (S)-Mephenytoin.47
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Figure 11. In vitro functional evaluation of rare and low-frequency variants 
in 4 ADME genes. (A) Uptake of 100μM [14C]-TEA by a wild-type and three 
mutated OCT1 proteins (p.A33V, p.Y91V, p.A407T) in transiently transfected 
HEK293 cells. (B) Concentration of [3H]-ES dependency by a wild-type and 
two mutated OATP1B1 proteins (p.V84L, p.V405F) in transiently transfected 
HEK293T cells. (C) Accumulated Calcein (%) compared to mock between a
wild-type and three mutated MDR1 proteins (p.G251R, p.L760V, p.E1129K). 
The efflux of MDR1 protein is conversely proportional to accumulated Calcein, 
which was measured by fluorescence intensity. (D) 4’-Hydroxylation of (S)-
Mephenytoin by a wild-type and two mutated CYP2C19 proteins (p.T210N, 
p.K273T). Results were shown as mean ± SEM. * P < 0.05, ** P < 0.01, ***P < 
0.001, WT , Wild-Type.
33
5. Targeted sequencing identified novel genetic determinants for the PK 
variability of Tacrolimus 
Tacrolimus is an immunosuppressive drug with the large inter-individual 
variances in PK profiles. Therefore, defining genetic determinants of PK variability 
may help adjusting proper dosing of Tacrolimus at an earlier stage. As reported 
previously, Coefficient of Variations (CV) of AUClast values was high in the two
cohorts, which were 48.86% and 59.24%, respectively (Figure 12A and 12C).
Target capture of 43 healthy volunteers in Phase 1 clinical trial of 1mg Tacrolimus 
showed that substantial portions of inter-individual variability in AUClast was 
accounted by CYP3A5*3 (rs776746, c.6986T>C). As expected from previous 
studies,48 CYP3A5*3 was the top component that can explain the variations in drug 
exposure (Figure 12B). The effect of the functionally impaired CYP3A5*3 allele on 
AUClast was also replicated in an independent cohort of 47 healthy individuals 
taking 2 capsules of 1mg Tacrolimus (Figure 12D). The CYP3A5*3 allele has been 
largely investigated, partly because the variants is common in the most of 
population. Therefore, for the drugs metabolized by CYP3A5, metabolizer types by 
CYP3A5*3 allele can be categorized into extensive, intermediate and poor 
metabolizers (EM, IM, and PM).33 Several variants showed the same trend to 
explain the variability of AUClast since they are in linkage disequilibrium with 
rs776746 (Figure 13A-F). Nevertheless, a part of people in PK outliers and 
extremes were not explained by CYP3A5*3 solely. In prior screening of genes with
known associations such as three canonical PK genes and other genes, only 
p.A503V (rs1057868, c.C1508T) of P450 oxidoreductase (POR) gene was 
confirmed to reduce the drug exposure specifically for CYP3A5 expressers (Figure 
14). This was consistent with the previous reports of POR*28.49-51 Since POR 
activity is highly coupled with the oxidative activity by CYP enzymes, the p.A503V 
variant may facilitate the enzyme activity by activating electron transfers.
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Figure 12. Variable drug exposure (AUClast) explained by metabolizing 
groups by CYP3A5*3 genotypes. The variability in AUClast was high as
47.86% (A, n=43) and 59.24% (C, n=47) when measured at CV. The 
CYP3A5*3 variant accounted for the variability of AUClast with statistical 
significances in two cohorts (B, n=43 and D, n=47). * P < 0.05, ** P < 0.01, 
***P < 0.001. EM, Extensive Metabolizer; IM, Intermediate Metabolizer; PM,
Poor Metabolizer.
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Figure 13. SNPs linked with CYP3A5*3(rs776746) and PK of Tacrolimus.
(A) LD blocks near CYP3A5*3 (rs776746, marked with an asterisk). Variants 
within ± 500kb of rs776747 were investigated from 43 samples and R’-square 
values were depicted in each block. These variants showed the same trend as 
CYP3A5*3 allele did with statistical significances at varying degrees. The plots 
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showed categorizing of AUClast by rs15524 ((B), CYP3A5, C>T), rs3823812
((C), CYP3A5, A>T), rs12360 ((D), CYP3A7, G>A), rs2257401 ((E), 
CYP3A7*2, C>G, p.T409R) and rs2242480 ((F), CYP3A4*1G, A>G). * P < 
0.05, ** P < 0.01, ***P < 0.001.
37
Figure 14. The POR*28 T allele of reducing drug exposure to Tacrolimus 
among CYP3A5 full expressers. Whereas the POR*28 CC genotype was 
absent in three EM of 43 samples (A), POR*28 T allele carriers of three EM of 
47 samples showed less exposures to Tacrolimus than non-carriers (B). * P < 
0.05.
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We further investigated the unknown genetic variants for associations with
fluctuating PK profiles. There was no significant association with any single variant 
for both sets. For rare variants of MAF ≤ 0.01, we performed the gene-based burden 
test by comparing means between carrier and non-carrier of rare variants within 
pooled 90 samples (Table 4). The test of nonsynonymous variants revealed that rare 
variants in UGT1A4 had the significantly different AUClast between carriers and
non-carriers (p = 0.0003 at MAF cutoff = 0.01). These rare variants in UGT1A4 
also influenced drug exposure within the PM group with the robust trend toward 
significance (p = 0.054 at MAF cutoff = 0.01). In the detailed examination of these 
variants in each set of 43 and 47, we discovered a number of rare variants (MAF ≤
0.01) in phenotypic extremes of 3 metabolizer groups by CYP3A5*3 (Figure 15). 
We discovered that upper phenotypic extremes of PM and IM in 43 samples shared 
one stop-gain variant (p.Q98X). Notably, the p.Q98X carrier of CYP3A5*3 IM was 
compound heterozygous with two additional frame-shift and missense variants. The 
p.L132P variant was found in a lower extreme of PM in 43 samples and expected to 
decrease drug exposure by increasing phase II metabolism of Tacrolimus. One 
additional p.R11W variant was found in one of EM but no significant effect on PK 
variability was detected. Though p.R11W (UGT1A4*4) showed the increased
activity for glucuronidation of Tacrolimus,28 the effect within EM by CYP3A5*3 
was insignificant. This suggested that UGT1A4 functions distinctively in the 
context of functionally disrupted CYP3A5. In a set of 47 samples, two rare variants 
(p.E50D and p.A58V) were discovered in lower extremes of PM and IM, 
respectively. These variants appeared in less than 0.1% of population, according to 
1000GP as listed (Table5).
Taken together, the PK variance can be explained more by POR*28 and rare 
variants of UGT1A4 (R2 = 37.7% and 47.7 %) than solely by CYP3A5*3 (R2 = 31.8%
and 41.7 %, respectively for 43 and 47 samples). To conclude, we could increase 
approximately 6% of explanatory information for the PK variability of Tacrolimus.
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Table 4. Gene-based burden test for rare variants of MAF 1%
Gene Group
T-test statistics Mean of dose-adjusted AUClast
P-value
Variants
Carrier
Variants
Non-carrier
UGT1A4
All 0.0003 24432.1 (5) 48434.5 (85)
*3/*3 PM 0.054 25490.4 (2) 63032.1 (48)
*1/*3 IM 0.518 26775.9 (2) 30646.9 (30)
*1/*1 EM NA 17627.6 (1) 24569.2 (7)
CYP2B6
All 6.40×10-5 35327.5 (2) 47368.6 (88)
*3/*3 PM NA NA (0) 61530.5 (50)
*1/*3 IM NA 35011.4 (1) 30256.3 (31)
*1/*1 EM NA 35643.6 (1) 21995.5 (7)
SCN5A
All 0.029 69741.0 (6) 45483.9 (84)
*3/*3 PM 0.292 73785.7 (5) 60168.8 (45)
*1/*3 IM NA 49517.4 (1) 29788.4 (31)
*1/*1 EM NA NA (0) 23701.5 (8)
POR
All 0.031 35563.8 (6) 47925.1 (84)
*3/*3 PM NA 55368.6 (1) 61656.2 (49)
*1/*3 IM 0.501 31602.8 (5) 30183.1 (27)
*1/*1 EM NA NA (0) 23701.5 (8)
BRCA1
All 4.67×10-14 22011.7 (2) 47671.2 (88)
*3/*3 PM NA NA (0) 61530.5 (50)
*1/*3 IM 0.129 22011.7 (2) 30964.5 (30)
*1/*1 EM NA NA (0) 23701.5 (8)
EGFR
All 0.202 63697.4 (4) 46329.1 (86)
*3/*3 PM 0.207 85442.2 (2) 60534.1 (48)
*1/*3 IM 0.033 41952.6 (2) 29635.1 (30)
*1/*1 EM NA NA (0) 23701.5 (8)
Only genes that showed statistical significance (P-value < 0.05) in any group were listed.
The number in parentheses represents the number of samples in carriers or non-carriers of 
variants of MAF 1%. PM, Poor Metabolizer; IM, Intermediate Metabolizer; EM, Extensive 
Metabolizer, NA; Not Available because less than one sample was detected  
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Figure 15. Rare variants in UGT1A4 carried by phenotypic extremes. Rare 
variants with bi-directional effects in UGT1A4 functions showed different drug 
exposure in phenotypic extremes of both sets. (A) The p.Q98X1) and compound 
heterozygote3) of p.Q98X and p.A58fs were discovered in two upper extremes of 
PM and IM. The p.L132P2) was identified in the lower extreme of PM. One 
additional p.R11W4) was found in one of EM but no significant effect was 
shown. (B) Three rare variants (p.E50D5), p.E454Q6) and p.A58V7)) were found 
in lower extremes of PM and IM, respectively.
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Table 5. The detailed information of rare variants in UGT1A4
Variant Protein rs ID AF 1 Carrier (Set 2)
1) c.C292T p.Q98X rs201323245 0.0004 Upper extreme of PM (43) 
2) c.T395C p.L132P rs72551337 0.0002 Lower extreme of PM (43) 
3)
c.[C292T]+
[74delG ; A325G] p.[A58fs] + [Q98X] NA NA
3 Upper extreme of IM (43) 
4) c.C31T p.R11W rs3892221 0.0140 One of EM (43)
5) c.G150C p.E50D rs45510694 0.001 Lower extreme of PM (47) 
6) c.G1360C p.E454Q NA NA One of IM (47)
7) c.C173T p.A58V rs141408391 0.002 Lower extreme of IM (47) 
The numbers in the first column are matched with ones in figure 15. AF, Allele Frequency;
NA, Not Available.
1 Allele frequency screened from 1000 GP.
2 The number in parentheses represents the number of samples for the cohorts, of which 
corresponding carrier are included in.
3 The c. A325G (rs539093785) appeared in 0.02% of 1000 GP. However, the compound 
heterozygote of these three variants has not been reported yet. 
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IV. DISCUSSION
In the present study, we developed the optimized probe set based on MIP, 
which can be readily applicable for pharmacogenomics analysis. Through 
modifications from previously reported MIP methods, this platform featured less 
costly and laborious preparation protocol. The genotyping performance was
comparable to the existing platforms as measured by PPV and sensitivity. 
Nevertheless, there was a part of genes that were not perfectly captured by this 
panel. We speculated that the sequence similarity of ADME genes might have
impeded the capture performance of a part of probes. We expected that further serial 
rebalancing could have improved the coverage significantly as we achieved in the 
first rebalancing. One drawback of microarray-based MIP synthesis is that it is 
impossible to sort poorly performing MIPs out from all probes. Therefore, we 
mixed the original probes with the rebalanced probes without eradicating poorly 
performing MIPs. We expected that a panel of selected probes with the high
performance would improve the coverage a lot higher in the future. 
Target capture and NGS of DNA sequences from 191 Koreans revealed 
unreported variants, especially ones in low frequency. Although 191 Koreans were
not sufficient to discover very rare variants, the trend of higher ratio of 
nonsynonymous variants at low frequency could be observed. Moreover, in silico
prediction programs expected that genetic variants in lower frequency were 
enriched for those with damaging effects. It is not to say all variants in low 
frequency were deleterious, but in vitro evaluation of 4 ADME genes implicates 
genetic variants at low frequency, which might have been missed out in past 
pharmacogenetic studies, may account for variable drug exposure and response.
Still, it is difficult to decide how in vitro results can be reflected in clinical practice. 
Evaluating the clinical meaning of newly discovered rare variants remains as an 
issue to adopt for decision making in clinical practice.
Application of the optimized MIP set to the participants in phase 1 clinical 
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trials proved the utility of this platform. Aside from CYP3A5*3, an established
index variant for the variability, POR*28 and rare variants in UGT1A4 were
revealed to be the account for the part of variable drug exposure to Tacrolimus. The 
drug exposure by POR*28 was significantly decreased only in the context of fully 
functional CYP3A5. On the other hand, rare variants in UGT1A4 showed bi-
directional effects on drug exposure and significant influence in the context of 
functionally impaired CYP3A5. Interestingly, while p.L48V (UGT1A4*3), a 
commonly discovered variant in both sets, showed no significant functional effects 
on drug exposure, only variants of low frequency had impacts on the extent of drug 
exposure. To the best of our knowledge, this is the first time to report the 
association of rare genetic variations of UGT1A4 with the PK of Tacrolimus. Taken 
together, we expected to increase approximately 6% of explanatory information by 
adopting POR*28 and pooled rare variants of UGT1A4 as genetic determinants of a 
model for the PK variability of Tacrolimus. 
Though UGT1A4 was pointed as a major contributor of Tacrolimus 
glucuronidation,28 it is still unclear that how glucuronidation by UGT1A4 interplays 
with oxidative metabolisms by CYP 3A enzymes. In addition, the conjugated drugs
to glucuronide could be recycled via enterohepatic circulation, affecting the drug 
exposure up to the total clearance of drugs. To further explore the extent of 
contribution of glucuronidation by UGT1A4, the difference in enzyme kinetics by 
mutated proteins should be evaluated in vitro. Also, the sample size was insufficient 
to discover a great diversity of rare variants in current cohorts, which resulted in 
discovering only suggestive trend toward significance in association tests. Therefore, 
further validation of our findings in larger cohorts of healthy volunteers and patients 
is needed. 
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V. CONCLUSION
The present study showed that the optimized probe set based on MIP is a 
readily applicable platform to capture common markers and unrevealed rare 
variants in ADME and PD genes for pharmacogenomic analysis. Target capture and 
NGS of DNA sequences from 191 Koreans showed the unreported low-frequency 
variants were enriched for nonsynonymous variants especially with potentially 
damaging effects. Moreover, relatively rare variants might have been
underestimated in previous pharmacogenetic studies, in spite of functional impacts, 
as shown by in vitro functional validation in 4 ADME genes. When applying the 
panel to healthy volunteers in phase 1 clinical trials, beyond known markers, novel 
genetic determinants were identified as contributing factors to variable extents of 
exposure to Tacrolimus. One of notable findings was the contribution of rare 
variants in UGT1A4 for PK pathway of Tacrolimus. Taken together, these results 
implicate that not only common but also rare variants are worth being considered 
for pharmacogenomic analysis. We also present a proof of concept that NGS-based 
screening of pharmacogenes at earlier phase of clinical trials can help understanding 
novel metabolic pathways of drugs by taking unknown rare and low-frequency 
genetic variations into account.
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ABTRACT (IN KOREAN)
분자 도치 프로브 (MIP) 기반 다중 타깃 포획을 이용한
약물유전체 분석
<지도교수 이 민 구>
연세대학교 대학원 의과학과
한 수 민
분자 도치 프로브 (MIP)에 기반한 타깃 포획 방법을 응용하여, 
약물유전체 분석을 위한 타깃 시퀀싱에 적합화한 프로브 세트를 개발하
였다. 이 플랫폼의 프로브들은 80개의 약물의 흡수, 분포, 대사, 배설 및
반응에 중요한 유전자와 현재까지 잘 알려진 유전학적 바이오 마커를 포
획하도록 디자인되었다. 반복적인 재조정을 통하여 적합화된 이 플랫폼을
이용하여 96%의 타깃 유전자와 바이오 마커에 대한 유전형을 99.8%의
정확도로 얻을 수 있었다. 이 플랫폼은 microarray에서 합성한 후 증폭한
이중 서열의 분자 도치 프로브 방법을 응용한 것으로, 프로브를 위한 준
비가 간편하고 가격이 저렴한 장점이 있다. 이 플랫폼을 191명의 건강한
한국인에 적용하여 목표 유전자와 마커들을 시퀀싱한 결과, 약물의 체내
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동태와 관련된 유전자에서, 보고된 바 없는 드문 빈도로 나타나는 변이들
을 발견할 수 있었다. 기능적 변화를 예측하는 컴퓨터 프로그램을 이용하
여 발견된 변이에 의한 효과를 예측하였을 때, 비교적 드문 빈도로 나타
나는 유전자 변이들이 기능적 변화를 더 크게 일으킬 것으로 예측되었다. 
이 중 4개의 약물 수송체 및 대사 효소 유전자에서 나타나는 드문 빈도
의 유전자 변이들을 골라, 체외(in vitro) 실험에서 실제 변이가 있는 단백
질의 기능이 변화되는지 확인하였다. 대부분의 변이들이 단백질이 표준
기질을 수송하거나 대사시키는 기능을 저해하는 것을 확인할 수 있었다. 
이 결과를 통하여 기존의 약물유전학 연구에서 중요성을 두지 않았던 드
문 변이 또한 약물의 반응 및 노출 정도에 영향을 미칠 가능성이 있다는
것을 알 수 있었다. 개인간 약물의 동태 및 반응 차이가 크다고 알려진
약물의 유전적 소인을 분석하기 위하여, 면역억제제인 Tacrolimus를 투여
받은 90명의 1단계 임상 시험의 참여자에 이 플랫폼을 적용하였다. 알려
진 바와 같이 CYP3A5 유전자에 *3로 명명된 변이에 의해 약물 동태가
통계적으로 유의하게 차이 나는 것을 확인하였다. 이 외에도, POR*28과
UGT1A4의 드문 변이들이 개인간 약물 동태의 차이를 설명할 수 있음을
확인하였다. POR*28은 특히 CYP3A5의 발현이 정상적인 그룹에서 약물에
대한 노출 정도를 줄이는 것을 확인하였다. 반면, UGT1A4의 드문 변이들
은 특히 CYP3A5의 발현이 적은 그룹 내의 약물 동태의 차이가 크게 나
타나는 피험자에게서 발견되었다. UGT1A4는 Tacrolimus의 glucuronidation
에 주요한 효소로 알려져 있기 때문에, 변이에 의한 효소 기능의 차이가
체내 약물 동태의 차이를 유발하였다고 생각할 수 있다. 현재까지 알려진
바에 의하면, UGT1A4의 변이가 Tacrolimus의 약물 동태 차이와 연관이 있
다는 보고는 없었다. 결론적으로 POR*28과 UGT1A4의 드문 변이들을 고
려하면 CYP3A5*3만 고려하였을 때보다 Tacrolimus의 약물 동태의 차이를
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약 6% 더 설명할 수 있었다. 이상의 결과를 통하여 약물유전학 연구와
테스트에서 인구 집단에서 흔하게 나타나는 변이뿐만 아니라 드물게 나
타나는 변이도 고려될 필요가 있음을 보였다. 또한, 임상시험의 초기 단
계에서 이와 같은 약물유전학 연구를 가능하게 하는 플랫폼을 적용함으
로써, 임상시험 중인 약물의 새로운 대사 경로나 작용 기전을 이해하는
것을 도울 수 있을 수 있음을 보였다. 덧붙여, 본 연구에서 확립한 플랫
폼이 약물유전학적 연구에 바로 적용할 수 있는 효율적인 도구이며, 약물
반응 및 동태의 개인차를 설명하는 데에도 활용이 가능함을 보였다.
핵심되는 말: 약물유전학, 타깃시퀀싱, 분자 도치 프로브 (MIP), 희귀 변
이(rare variants), 약물동태에 관련된 유전자들(ADME genes)
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